Trial Profile
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Gefitinib in Combination With MEDI4736 (Anti PD-L1) in Subjects With Non-Small Cell Lung Cancer(NSCLC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Jun 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors AstraZeneca; AstraZeneca KK; MedImmune
- 12 Apr 2021 Status changed from active, no longer recruiting to completed.
- 05 Oct 2020 Results published in the British Journal of Cancer
- 16 Jul 2019 Planned End Date changed from 11 Jun 2019 to 31 Dec 2021.